Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1627
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17428505 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Final Rejection | GENZYME CORPORATION |
| 19347686 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | Final Rejection | Helsinn Healthcare SA |
| 18603065 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | Final Rejection | The Regents of the University of California |
| 17691745 | HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 18548797 | METHOD OF INCREASING THE POPULATION OF BLAUTIA SPP. IN THE GUT MICROBIOME | Non-Final OA | DSM IP Assets B.V. |
| 17998433 | METHODS OF TREATING SJÖGRENS SYNDROME | Final Rejection | Vanderbilt University |
| 18370558 | TREATMENTS FOR BLOOD-BRAIN BARRIER DYSFUNCTION AND RECURRENT SEIZURES USING NOX/LOX/COX INHIBITORS | Non-Final OA | University of Kentucky Research Foundation |
| 18278904 | COMPOUNDS AND METHODS FOR TREATING CONGENITAL ERYTHROPOIETIC PORPHYRIA | Non-Final OA | REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18237360 | METALLOENZYME MODULATORS | Non-Final OA | Regents of the University of Minnesota |
| 18571817 | PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 18915730 | METHODS OF TREATMENT USING A STATIN AND A CANNABINOID | Final Rejection | Indication BioScience LLC |
| 18300984 | Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases | Final Rejection | YALE UNIVERSITY |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | Non-Final OA | MANNKIND CORPORATION |
| 18283851 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Final Rejection | CHIESI FARMACEUTICI S.P.A. |
| 18040515 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | Non-Final OA | Temple University-Of The Commonwealth System of Higher Education |
| 18571754 | Strained bi-functionalized trans-cyclooctenes | Non-Final OA | Stichting Radboud Universiteit |
| 18252760 | METHODS OF TREATMENT OF LIVER FAILURE | Non-Final OA | GENFIT |
| 18568160 | EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER | Non-Final OA | NATCO PHARMA LIMITED |
| 18019302 | THERMO-SENSITIVE PERMEATION ENHANCING FORMULATIONS FOR DRUG DELIVERY | Final Rejection | Children's Medical Center Corporation |
| 18455767 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Non-Final OA | HOTSPOT THERAPEUTICS, INC. |
| 18018885 | MULTI-EFFICACY PYRAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | Non-Final OA | SHENZHEN OLIVE BIOPHARMACEUTICALS CO., LTD |
| 18276120 | AMISELIMOD FOR PREVENTING, TREATING OR AMELIORATING ULCERATIVE COLITIS | Non-Final OA | Bausch Health Ireland Limited |
| 18259184 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | Non-Final OA | AMTIXBIO CO., LTD. |
| 18273575 | TOPICAL COMPOSITION COMPRISING PREGABALIN | Final Rejection | EGIS GYÓGYSZERGYÁR ZRT. |
| 18038667 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF FIBROTIC DISEASES | Non-Final OA | Galapagos NV |
| 18037405 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY FIBROSIS | Final Rejection | Pulmosim Therapeutics LLC |
| 18247928 | O-ACETYLSERINE FOR THE USE THEREOF IN THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE AND THE ASSOCIATED DISEASES | Final Rejection | UNIVCERSITE PARIS-SACLAY |
| 18130943 | TREATMENT OF SKIN DISEASES | Final Rejection | Ichilov Tech Ltd. |
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | Non-Final OA | Ashvattha Therapeutics, Inc. |
| 18001487 | TREATMENT METHODS AND FORMULATIONS | Non-Final OA | Curtin University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy